FINANCE MONTHLY CEO AWARDS 2014

EUROPE

a Vision

in the UK. The highly specialised plant, in Wolverhampton, puts the company in a strong position to compete on price as well as product performance.

And John is working on a global level, driving exports to Europe, Asia and Australasia, and more recently Scandinavia. His vision is to achieve global market leadership, with an eminently strong and expanding product range.

“I’m excited about the prospects for the company,” says John, “we’re working now on new products and applications for Fantex, and this is taking the company into new markets with true growth potential”.

What next for All in One Medical?

John is steering the company through a programme of broadening out the product range. By adding Fantex protective coatings to solids, liquids and gels, they’re able to explore new product ideas across a wide range of industry sectors.

This opens up a whole new world of possibilities where hygiene is an issue.

In the dairy industry, they are developing a hygienic wash for cows’ teats.

And talks are currently under way with a number of garment manufacturers. Applying Fantex to fabrics helps keep them clean, fresh

and odour free. Clothing retailers and workwear manufacturers are naturally very interested.

They’re also working on applications within the nursing and care homes industry, including the development of hygienic seat covers for wheelchairs.

The company wants to go deeper into the medical industry too. Its core values are about responding to the needs of people, and their protection from infection in a medical environment. This extends to healthcare professionals, patients and the general public.

John is currently engaged in recruiting additional management talent to see the business through its next phase of product and market expansion.

already offers huge scope for growth across the world.

Beringea Partner, Stephane Mery, who led the transaction commented: “I am thrilled with our investment, and to be supporting such a great team. I am also delighted that our investment is helping a British company bring its manufacturing back to the UK. DCCL’s highly

specialised plant in Wolverhampton allows the Company to successfully outperform Chinese manufacturers on both quality and price.”

And it doesn’t stop there. All in One Medical is pursuing a programme of pioneering research and cutting edge innovation right now, paving the way for rapid and massive growth.

With expansive plans afoot to grow export markets and push the boundaries of innovation, John needs a good team around him to deliver the next generation of Fantex products.

Whilst All in One Medical is in the enviable position of producing products that perform such an

Things are moving forward quickly, with the company applying for four new patents for Fantex in the last month. Fantex provides an excellent opportunity to improve the lives of people, to make a real difference – the essence of the company’s raison d’être. And with hospital-acquired infections being the 4th biggest killer in the US, it’s a very welcome breakthrough.

And financially? The company continues on its path of solid profit growth, delivering on the hopes and expectations of its stakeholders.

And what next for John Hawkins?

important, life-saving function with little competition, John is not complacent

“As CEO it’s my duty to ensure we continue to drive high standards, infallible product performance and impeccable customer service across our global territories. We need to educate our markets too, so they understand the far reaching benefits of using our products. There is a lot of work to be done, and I’m looking forward to it”.

l Website: www.allinonemedical.com FINANCEMONTHLY 39